Squamous Cell Carcinoma of Head and Neck clinical trials

Every programme with a company-led study here in the last two years, whatever its size: 91 programmes from 69 companies, 47 with this as their studies’ main aim; 11 with a live phase 3 study; 13 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programmes are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

35 more in limited or earlier use — sign in to see them, free.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 in phase 3 with the nearest primary completion, of 91 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (13)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

• Dec 2026 est.Curcumin/Polyphenols-containing Botanical Agent APG-157 · Aveta Biomics, Inc. · Phase 2 main aimNCT05312710 Safety and Efficacy of APG-157 in Head and Neck Cancer — primary endpoint: Imaging to assess drug's ability to impact tumor size · 24 enrolled
• Dec 2026 est.TH9619 · One-carbon Therapeutics AB · Phase 2 named, not the main aimNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors — primary endpoint: Frequency of treatment-emergent adverse events (TEAEs) · 43 enrolled
• Dec 2026 est.Anti-PD-1/LAG-3 Bispecific Antibody AK129 · Akeso · Phase 2 main aim+ Pemetrexed, Paclitaxel, Carboplatin vs Cetuximab+ Pemetrexed, Paclitaxel, Carboplatin vs Cisplatin+ Pemetrexed, Paclitaxel, Carboplatin vs FluorouracilNCT06943820 AK129 Combination Therapy for Advanced Solid Tumors — primary endpoint: Frequency and severity of adverse events (AEs) ,Clinically significant abnormal laboratory results · 230 enrolled

10 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.